VolitionRx Lands $7.3M French Sepsis Trial, Grows Revenue 40% to $1.7M
In 2025 VolitionRx received its first clinical order for Nu.Q Cancer assays and inclusion of its Nu.Q NETs sepsis test in a $7.3M French government trial. Full-year revenue rose 40% to $1.7M (Q4 +133%), operating expenses fell 17%, net loss dropped 14% and post-year-end funding hit $8.3M.
1. Business Milestones
VolitionRx achieved its first clinical order for Nu.Q Cancer assays for lung cancer certification and saw its Nu.Q NETs sepsis assay included in a $7.3 million government-backed interventional trial in France. The company is engaging with around 10 leading diagnostic and liquid biopsy firms in various stages of licensing discussions, from due diligence to contract negotiation.
2. Financial Performance
Full-year 2025 revenue rose 40% to $1.7 million, driven by a 133% jump in Q4 sales. Operating expenses decreased by $4.8 million (17%), net loss narrowed by 14%, and net cash used in operating activities fell 24% to $19.7 million.
3. Post-Year-End Funding
Subsequent to year end, VolitionRx raised $5.4 million via at-the-market equity sales, $1.9 million from a convertible note and warrant issuance, and secured $1 million of non-dilutive funding from Walloon Region agencies, with an additional $0.9 million expected over the next 12 months based on milestone achievements.